Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Breast cancer may harm egg quality before treatment even starts

NCT ID NCT07148141

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how breast cancer itself may affect a woman's ability to have children later. Researchers are comparing egg quality and hormone responses in 100 women with breast cancer versus healthy egg donors. The goal is to understand why cancer can reduce the number and quality of eggs retrieved for fertility preservation, and to find ways to improve future fertility treatments based on cancer type.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Jan 2019

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Breast cancer patients and oocytes donors

Ages

18 to 38 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women above 18 years old and below 38 years old * First hormonal stimulation cycle * No dysovulation * No cancer treatments prior fertility preservation (tumour resection, chemotherapy, radiotherapy) * Women capable of giving written informed consent to participate in the research study * Affiliated to social welfare service Exclusion Criteria: * Women below 18 years old and above 38 years old * Endocrine disease * Endometriosis * Any cancer treatments prior fertility preservation (tumour resection, chemotherapy, radiotherapy) * Previous hormonal stimulation cycle of less than six months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU Clermont-Ferrand

    Clermont-Ferrand, Auvergne Rhones-Alpes, 63000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.